Blog

Core One Labs Nearing GMP Production as Canada’s Province of Alberta Announces Game Changing Legislation

Oct 10 • 4 min read

Core One Labs Inc. (CSE: COOL | OTC: CLABF | Frankfurt: LD6, WKN: A3CSSU), is pleased to announce that it is nearing good manufacturing practices (GMP) production of its psychedelic compounds, as the Company has progressed its negotiations with a certified facility and is developing a detailed plan to provide high quality and affordable psychedelic medicine…

ALTRD.TV’s Open Minds Documentary Explores the Promising Future of Psychedelic Medicine

Oct 10 • 3 min read

ALTRD.TV, the streaming network for progressive culture, released the trailer for its new upcoming series Open Minds: Exploring Psychedelic Medicine, coming in 2023. The series concentrates on the resurgence of psychedelic research for mental health treatments, with leading industry experts from The Chopra Foundation, MAPS, The McKenna Academy of Natural Philosophy, Cybin Inc. (NYSE AMERICAN:CYBN |…

Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia

Oct 10 • 2 min read

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has initiated a preclinical toxicity study of its novel time-released, dosage controlled formulation of ketamine, designated as SP-26, for the treatment of fibromyalgia. “We are working closely with our joint venture partner Zylö Therapeutics…

Reunion Neuroscience Inc. Announces Executive Changes

Oct 10 • 2 min read

Reunion Neuroscience Inc. (TSX: REUN | NASDAQ: REUN), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds, today announced that Ronan Levy has resigned as Director of the Company and Paula Amy Hewitt has resigned as General Counsel & Corporate Secretary,…

The MindMed Chronicles: An Interview With Robert Barrow, the CEO of MindMed

Oct 8 • 2 min read

The following is a continuation of all our recent MindMed coverage. Over the past few weeks, we published a few conversations with Jake Freeman. Click here to watch part 1 of the Jake Freeman interview. Click here to watch part 2 of the Jake Freeman interview. Before that, it all began with a two-part interview…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560